Conferences

ecancer travels so that you don't have to. Expore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

AACR 2018

14 - 18 Apr 2018
McCormick Place North/South, Chicago, United States of America
Dose escalation of durvalumab with tremelimumab for metastatic urothelial cancer
Dr Arjun Balar - NYU Langone Medical Center, New York, USA
Dose escalation of durvalumab with tremelimumab for metastatic urothelial cancer ( Dr Arjun Balar - NYU Langone Medical Center, New York, USA )
25 Apr 2018
Neoadjuvant nivolumab for resectable lung cancer
Dr Drew Pardoll - Johns Hopkins Medicine, Baltimore, USA
Neoadjuvant nivolumab for resectable lung cancer ( Dr Drew Pardoll - Johns Hopkins Medicine, Baltimore, USA )
25 Apr 2018
Developing off-the-shelf CAR T cells with stem cell libraries
Dr Bob Velamehr - Fate Therapeutics, La Jolla, USA
Developing off-the-shelf CAR T cells with stem cell libraries ( Dr Bob Velamehr - Fate Therapeutics, La Jolla, USA )
25 Apr 2018
Biomarkers of pembrolizumab response in head and neck cancer
Dr Tanguy Seiwert - The University of Chicago Medicine, Chicago, USA
Biomarkers of pembrolizumab response in head and neck cancer ( Dr Tanguy Seiwert - The University of Chicago Medicine, Chicago, USA )
25 Apr 2018
Phase I taselisib results and a cell-free DNA assay
Dr José Baselga - Memorial Sloan Kettering Cancer Center, New York, USA
Phase I taselisib results and a cell-free DNA assay ( Dr José Baselga - Memorial Sloan Kettering Cancer Center, New York, USA )
25 Apr 2018
Safety indications in mouse models treated with full doses of MEK inhibitors and...
Dr Carmine Fedele - Laura and Isaac Perlmutter Cancer Center at New York Univers...
Safety indications in mouse models treated with full doses of MEK inhibitors and SHP099 ( Dr Carmine Fedele - Laura and Isaac Perlmutter Cancer Center at New York University Langone Medical, New York, USA )
25 Apr 2018
A variety of approaches to measure the efficacy of PARP inhibitors
Dr Elisabetta Leo - AstraZeneca, Cambridge, UK
A variety of approaches to measure the efficacy of PARP inhibitors ( Dr Elisabetta Leo - AstraZeneca, Cambridge, UK )
25 Apr 2018
Development and clinical indications of PARP inhibitors
Dr Mark O'Connor - AstraZeneca, Cambridge, UK
Development and clinical indications of PARP inhibitors ( Dr Mark O'Connor - AstraZeneca, Cambridge, UK )
25 Apr 2018
Mechanisms and prospects of a novel CDK9 inhibitor for DLBCL
Dr Susan Galbraith - AstraZeneca, Cambridge, UK
Mechanisms and prospects of a novel CDK9 inhibitor for DLBCL ( Dr Susan Galbraith - AstraZeneca, Cambridge, UK )
25 Apr 2018
Front-line therapy of DIPG using IDO inhibitor with radiation and chemotherapy
Dr Theodore Johnson - Georgia Cancer Center, Augusta, USA
Front-line therapy of DIPG using IDO inhibitor with radiation and chemotherapy ( Dr Theodore Johnson - Georgia Cancer Center, Augusta, USA )
25 Apr 2018
Impact of microbiome on head and neck cancers
Dr Young Jun Kim - Vanderbilt-Ingram Cancer Center, Nashville, USA
Impact of microbiome on head and neck cancers ( Dr Young Jun Kim - Vanderbilt-Ingram Cancer Center, Nashville, USA )
25 Apr 2018
First-in-human trial results of RET targeted BLU-667
Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA
First-in-human trial results of RET targeted BLU-667 ( Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA )
25 Apr 2018
Treating RET alterations with novel therapy BLU-667
Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA
Treating RET alterations with novel therapy BLU-667 ( Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA )
25 Apr 2018
AKT inhibitors in research and application
Dr Brian Schwartz - ArQule, Burlington, USA
AKT inhibitors in research and application ( Dr Brian Schwartz - ArQule, Burlington, USA )
25 Apr 2018
Tandem duplications in triple negative breast cancer
Dr Ed Liu - The Jackson Laboratory, Bar Harbor, USA
Tandem duplications in triple negative breast cancer ( Dr Ed Liu - The Jackson Laboratory, Bar Harbor, USA )
25 Apr 2018
Increasing diversity through the NCI SBIR development centre
Dr Christie Canaria - National Cancer Institute, Rockville, USA
Increasing diversity through the NCI SBIR development centre ( Dr Christie Canaria - National Cancer Institute, Rockville, USA )
25 Apr 2018
The importance of online patient groups and 'The ROS1ders'
Janet Freeman-Daily - The ROS1ders
The importance of online patient groups and 'The ROS1ders' ( Janet Freeman-Daily - The ROS1ders )
25 Apr 2018
Effects of dasatinib on xenograft lung tumour models with YES1 overexpression
Dr Irati Garmendia - University of Navarra, Pamplona, Spain
Effects of dasatinib on xenograft lung tumour models with YES1 overexpression ( Dr Irati Garmendia - University of Navarra, Pamplona, Spain )
25 Apr 2018
Analysis tools for NCI genomic databases
Dr Jean Claude Zenklusen - National Cancer Institute, Rockville, USA
Analysis tools for NCI genomic databases ( Dr Jean Claude Zenklusen - National Cancer Institute, Rockville, USA )
25 Apr 2018
Results from GOBACK: Non-chromosomal birth defects linked with cancer
Dr Jeremy Schraw - Baylor College of Medicine, Houston, USA
Results from GOBACK: Non-chromosomal birth defects linked with cancer ( Dr Jeremy Schraw - Baylor College of Medicine, Houston, USA )
25 Apr 2018
A link between non-chromosomal birth defects and cancer
Dr Jeremy Schraw - Baylor College of Medicine, Houston, USA
A link between non-chromosomal birth defects and cancer ( Dr Jeremy Schraw - Baylor College of Medicine, Houston, USA )
25 Apr 2018
Novel gene biomarkers in multiple cancers derived from non-malignant breast phen...
Jon Obenauer - Rancho BioSciences, Rancho Santa Fe, USA
Novel gene biomarkers in multiple cancers derived from non-malignant breast phenotypes ( Jon Obenauer - Rancho BioSciences, Rancho Santa Fe, USA )
25 Apr 2018
Reducing recurrence of advanced melanoma with pembrolizumab
Prof Alex Eggermont - Paris-Sud University, Paris, France
Reducing recurrence of advanced melanoma with pembrolizumab ( Prof Alex Eggermont - Paris-Sud University, Paris, France )
25 Apr 2018
Results of KEYNOTE-054; melanoma patients treated with pembrolizumab.
Prof Alex Eggermont - Paris-Sud University, Paris, France
Results of KEYNOTE-054; melanoma patients treated with pembrolizumab. ( Prof Alex Eggermont - Paris-Sud University, Paris, France )
25 Apr 2018
Clinical development and economic prospects of CAR T cell immunotherapies
Dr Bob Velamehr - Fate Therapeutics, La Jolla, USA
Clinical development and economic prospects of CAR T cell immunotherapies ( Dr Bob Velamehr - Fate Therapeutics, La Jolla, USA )
25 Apr 2018
Theranostic imaging of lymphoma using radiolabelled αCD19-antibodies
Dr Dominik Sonanini - Tübingen University Hospital, Tübingen, Germany
Theranostic imaging of lymphoma using radiolabelled αCD19-antibodies ( Dr Dominik Sonanini - Tübingen University Hospital, Tübingen, Germany )
25 Apr 2018
Response and safety profile of neoadjuvant nivolumab for resectable lung cancer
Dr Drew Pardoll - Johns Hopkins Medicine, Baltimore, USA
Response and safety profile of neoadjuvant nivolumab for resectable lung cancer ( Dr Drew Pardoll - Johns Hopkins Medicine, Baltimore, USA )
25 Apr 2018
Doubled survival in metastatic lung cancer with combination therapy
Dr Leena Gandhi - NYU Langone Medical Center, New York, USA
Doubled survival in metastatic lung cancer with combination therapy ( Dr Leena Gandhi - NYU Langone Medical Center, New York, USA )
25 Apr 2018
Combined immuno-chemotherapy improves survival and responses in metastatic lung ...
Dr Leena Gandhi - NYU Langone Medical Center, New York, USA
Combined immuno-chemotherapy improves survival and responses in metastatic lung cancer ( Dr Leena Gandhi - NYU Langone Medical Center, New York, USA )
25 Apr 2018
Results from CheckMate-227 : Immune combination reaches PFS endpoint
Dr Matthew Hellmann - Memorial Sloan Kettering Cancer Center, New York, USA
Results from CheckMate-227 :  Immune combination reaches PFS endpoint ( Dr Matthew Hellmann - Memorial Sloan Kettering Cancer Center, New York, USA )
25 Apr 2018
How the SBIR development centre funds cancer initiatives
Michael Weingarten - National Cancer Institute, Rockville, USA
How the SBIR development centre funds cancer initiatives ( Michael Weingarten - National Cancer Institute, Rockville, USA )
25 Apr 2018
Supporting technological initiatives in low and middle income countries
Dr Paul Pearlman - National Cancer Institute, Rockville, USA
Supporting technological initiatives in low and middle income countries ( Dr Paul Pearlman - National Cancer Institute, Rockville, USA )
25 Apr 2018